Aclaris Therapeutics, Inc. Financing Cash Flow
Aclaris Therapeutics, Inc. (ACRS) reported Financing Cash Flow of $57.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $91.00K.
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $57.78M.
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$2.53M, a 103.40% decline year-over-year.
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$3.04M, a 13936.36% decline year-over-year.
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$5.86M, a 107.86% decline from fiscal 2024.
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $74.54M, a 179.10% increase from fiscal 2023.
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $26.71M, a 63.35% decline from fiscal 2022.
- Aclaris Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $72.87M, a 67.62% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $57.87M 10-Q · filed 2026-08-06 | $55.34M derived: sum of 3 quarters · filed 2026-08-06 | $52.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $57.78M 10-Q · filed 2026-05-07 | $55.25M derived: sum of 2 quarters · filed 2026-05-07 | $52.20M derived: sum of 3 quarters · filed 2026-05-07 | $52.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.58M derived: sum of 2 quarters · filed 2026-02-26 | -$5.59M derived: sum of 3 quarters · filed 2026-08-06 | -$5.86M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.05M derived: sum of 2 quarters · filed 2026-08-06 | -$3.33M 10-Q · filed 2025-11-06 | $71.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$284.00K 10-Q · filed 2026-08-06 | $74.30M derived: sum of 3 quarters · filed 2026-08-06 | $74.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$275.00K 10-Q · filed 2026-05-07 | $74.31M derived: sum of 2 quarters · filed 2026-05-07 | $74.33M derived: sum of 3 quarters · filed 2026-05-07 | $74.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $74.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $74.60M derived: sum of 2 quarters · filed 2026-02-26 | $74.59M derived: sum of 3 quarters · filed 2026-02-26 | $74.54M 10-K · filed 2026-02-26 |
| 2024-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $11.00K derived: sum of 2 quarters · filed 2025-11-06 | -$44.00K 10-Q · filed 2025-11-06 | $5.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$66.00K 10-Q · filed 2025-08-07 | -$17.00K derived: sum of 3 quarters · filed 2025-08-07 | -$104.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$55.00K 10-Q · filed 2025-05-08 | -$6.00K derived: sum of 2 quarters · filed 2025-05-08 | -$93.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$38.00K derived: sum of 2 quarters · filed 2025-02-27 | $26.71M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $26.66M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $26.74M 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $26.00K derived: sum of 2 quarters · filed 2024-02-27 | $72.84M derived: sum of 3 quarters · filed 2024-02-27 | $72.87M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $72.80M derived: sum of 2 quarters · filed 2023-11-06 | $72.83M 10-Q · filed 2023-11-06 | $72.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $72.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $72.84M 10-Q · filed 2023-08-07 | $72.84M derived: sum of 3 quarters · filed 2024-02-27 | $61.27M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $30.00K 10-Q · filed 2023-05-08 | $28.00K derived: sum of 2 quarters · filed 2024-02-27 | -$11.54M derived: sum of 3 quarters · filed 2024-02-27 | $124.33M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$11.57M derived: sum of 2 quarters · filed 2024-02-27 | $124.30M derived: sum of 3 quarters · filed 2024-02-27 | $225.05M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$11.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $124.30M derived: sum of 2 quarters · filed 2022-11-08 | $225.05M 10-Q · filed 2022-11-08 | $232.88M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $135.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $236.62M 10-Q · filed 2022-08-03 | $244.45M derived: sum of 3 quarters · filed 2023-02-23 | $244.17M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $100.75M 10-Q · filed 2022-05-10 | $108.58M derived: sum of 2 quarters · filed 2023-02-23 | $108.30M derived: sum of 3 quarters · filed 2023-02-23 | $108.20M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $7.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $7.55M derived: sum of 2 quarters · filed 2023-02-23 | $7.45M derived: sum of 3 quarters · filed 2023-02-23 | $18.37M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$278.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$375.00K derived: sum of 2 quarters · filed 2021-11-02 | $10.54M 10-Q · filed 2021-11-02 | -$19.47M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $10.82M 10-Q · filed 2021-08-05 | -$19.19M derived: sum of 3 quarters · filed 2022-02-24 | -$19.26M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $10.92M 10-Q · filed 2021-05-07 | -$19.09M derived: sum of 2 quarters · filed 2022-02-24 | -$19.16M derived: sum of 3 quarters · filed 2022-02-24 | -$19.28M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$30.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$30.08M derived: sum of 2 quarters · filed 2022-02-24 | -$30.20M derived: sum of 3 quarters · filed 2022-02-24 | -$30.32M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$187.00K derived: sum of 2 quarters · filed 2020-11-04 | -$307.00K 10-Q · filed 2020-11-04 | $127.88M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$237.00K 10-Q · filed 2020-08-07 | $127.95M derived: sum of 3 quarters · filed 2021-02-25 | $127.97M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$120.00K 10-Q · filed 2020-05-07 | $128.06M derived: sum of 2 quarters · filed 2021-02-25 | $128.08M derived: sum of 3 quarters · filed 2021-02-25 | $127.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $128.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $128.20M derived: sum of 2 quarters · filed 2021-02-25 | $127.90M derived: sum of 3 quarters · filed 2021-02-25 | $128.26M 10-K · filed 2021-02-25 |
| 2018-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$280.00K derived: sum of 2 quarters · filed 2019-11-07 | $78.00K 10-Q · filed 2019-11-07 | $0.00 derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | -$299.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $59.00K 10-Q · filed 2019-08-08 | -$19.00K derived: sum of 3 quarters · filed 2020-02-25 | $80.90M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $358.00K 10-Q · filed 2019-05-08 | $280.00K derived: sum of 2 quarters · filed 2020-02-25 | $81.20M derived: sum of 3 quarters · filed 2020-02-25 | $100.53M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | -$78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $80.84M derived: sum of 2 quarters · filed 2020-02-25 | $100.18M derived: sum of 3 quarters · filed 2020-02-25 | $100.39M 10-K · filed 2020-02-25 |
| 2017-09-30 | $80.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $100.25M derived: sum of 2 quarters · filed 2018-11-06 | $100.46M 10-Q · filed 2018-11-06 | $198.73M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | $19.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $19.55M 10-Q · filed 2018-08-03 | $117.81M derived: sum of 3 quarters · filed 2019-03-18 | $117.82M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | $209.00K 10-Q · filed 2018-05-08 | $98.47M derived: sum of 2 quarters · filed 2019-03-18 | $98.49M derived: sum of 3 quarters · filed 2019-03-18 | |
| 2016-12-31 | $98.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $98.28M derived: sum of 2 quarters · filed 2019-03-18 | $116.83M 10-K · filed 2019-03-18 | |
| 2016-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $18.56M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $18.55M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $96.41M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |